AstraZeneca price target raised to 15,500 GBp from 14,200 GBp at Guggenheim

Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 15,500 GBp from 14,200 GBp and keeps a Buy rating on the shares, citing strong year-to-date performance, increased sales for Enhertu outside of the U.S. and Ultomiris, and SG&A leverage. The firm believes AstraZeneca, its preferred name among EU drugmakers for 2026, warrants a premium multiple to the group as “the most reliable growth story in EU Pharma” with potential for further catalyst-driven upside, the analyst tells investors.